<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099487</url>
  </required_header>
  <id_info>
    <org_study_id>1139</org_study_id>
    <nct_id>NCT02099487</nct_id>
  </id_info>
  <brief_title>Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma</brief_title>
  <official_title>Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide
      on survival and quality of life in elderly, poor performance status patients with newly
      diagnosed HGG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators designed this study with the aim to assess the effect of IMRT using VMAT
      rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in
      elderly, poor performance status patients with newly diagnosed HGG. The potential advantage
      of this approach is deliver a more selective irradiation to tumor's target with reducing the
      dose to normal brain and to allow the delivery of a higher dose, optimizing the therapeutic
      window.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>one year</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>one year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>one year</time_frame>
    <description>Incidence of hematologic and non hematologic severe toxicities (grade III/ IV) will evaluate using NCI-CTCA scale. Late toxicity will evaluate using CTCA 4.2</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL</measure>
    <time_frame>one year</time_frame>
    <description>Quality of Life</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>hypofractionated IMRT</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 70 years

          -  Karnosky performance status (KPS) ≤60

          -  Histologically confirmed HGG after tumor biopsy

               -  GBM

               -  Anaplastic Astrocytoma

               -  Anaplastic Oligoastrocytoma

               -  Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q

          -  Estimated survival ≥ 3 months.

          -  Normal liver, Kidney and bone marrow function

          -  Written informed consent

        Exclusion criteria:

          -  Prior radiation therapy

          -  Other primary cancer

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Study Director</role>
    <affiliation>Humanitas Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICH Humanitas Cancer Center</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>HGG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

